Table of Contents
Bristol Myers Squibb, on March 9, reported positive interim Phase 3 results from SUCCESSOR-2 in relapsed or refractory multiple myeloma, with oral mezigdomide in combination with carfilzomib and dexamethasone showing a statistically significant and clinically meaningful improvement in progression-free survival versus carfilzomib and dexamethasone alone.
The readout marks the first positive Phase 3 study for mezigdomide and the second for Bristol Myers Squibb’s CELMoD program. The result is relevant to treatment positioning in a relapsing disease setting. Bristol Myers Squibb and outside investigators described the regimen as a potential oral option for patients previously exposed to anti-CD38 and lenalidomide. The company said safety findings were consistent with the known profile of mezigdomide and the combination regimen, and that patients will continue to be followed for survival and safety.
Bristol Myers Squibb said data from SUCCESSOR-2 will be presented at a future medical meeting and shared with health authorities. No regulatory filing timeline or approval date was disclosed.
Sources: Reuters, Bristol Myers Squibb
Comments